TRANE-TECHNOLOGIES
17.8.2020 06:32:12 CEST | Business Wire | Press release
Global climate innovator Trane Technologies (NYSE: TT) announced today the launch of the Sintesis™ Balance CMAF, a fully electric single unit to heat and cool buildings. The air-cooled multi-pipe solution is the latest model in the Sintesis portfolio of high-performance indoor climate systems by Trane®, the company’s HVAC brand. It is initially available for customers in Europe, Middle East, and Africa.
Sintesis Balance is a fully electric unit that delivers hot and chilled water for heating and cooling. It is ideal for buildings with dynamic temperature requirements, such as schools, hotels, hospitals, retail centers, office buildings and theaters.
“The Sintesis Balance eliminates the need for separate boiler and chiller systems, and provides flexibility to meet comfort needs across climates, seasons, use and occupancy, as well as better use of floor space,” said José La Loggia, president of Trane Technologies’ Commercial HVAC in EMEA. “It also provides highly reliable operation, temperature control and indoor air quality. Most systems in Europe use gas or oil boilers, whereas this solution is fully electric. Since buildings contribute to about 15 percent of global carbon emissions, and heating and cooling represents about 35 percent of that, Sintesis Balance is also a major step on the path to electrification and decarbonization of buildings.”
The innovation contributes to Trane Technologies’ Gigaton Challenge, a goal to reduce customers’ greenhouse gas emissions by a billion metric tons by 2030. The unit recovers and repurposes energy without generating its own carbon emissions, significantly reducing fossil fuel use over typical systems that include both a boiler and a chiller. When drawing from a grid that generates electricity from renewable sources, Sintesis Balance has potential to be a zero-emissions solution.
Sintesis Balance Sustainability by the Numbers
Trane Sintesis Balance has an average Total Efficiency Ratio of 8.2; it generates 8 kW of simultaneous cooling and heating from only 1 kW of electric power. It also delivers a Coefficient of Performance (COP) of 3.35, the highest COP among air-sourced multi-pipe unit options. (COP is a measure of how much heat the system produces per unit of energy input).
The technology’s expanded operating map allows for temperature control even in very hot or cold climates. The heating capabilities of the unit make it a good choice for building applications in regions where ambient air temperatures go down to minus 18 degrees Celsius. The unit also can heat water up to 68 degrees Celsius.
Technical features of the Trane Sintesis Balance CMAF
- Trane Adaptive Refrigerant System™ automatically optimizes refrigerant charge in each operating mode and temperature condition, delivering additional performance and efficiency gains.
- Fully electric driven CMAF multi-pipe unit doesn’t generate direct greenhouse gas emissions beyond emissions from the electricity grid. It offers up to 350 percent higher efficiency compared to most gas boilers when delivering hot water for comfort heating systems.
- Configurability with three acoustic packages and efficiency levels to meet different building application requirements.
- New generation of Trane controls technology – Tracer Symbio™ 800 controller features advanced algorithms ensuring smooth, reliable operation with low cost of ownership. In addition, it also offers six arbitration choices to optimize performances for the application.
- Tracer Symbio 800 with TD7 AdaptiView™ touchscreen provides facility managers with user-friendly control of the unit. The controller allows them to remotely manage and respond to a variety of conditions and maintain efficient operation with various pre-programmed operating modes.
For more details of on the complete Trane portfolio of solutions for EMEA, please visit www.Trane.eu .
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
